Mizuho Securities analyst Uy Ear has maintained their neutral stance on NBIX stock, giving a Hold rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Uy Ear’s rating is based on several factors concerning Neurocrine’s recent financial performance and future projections. The company’s fourth-quarter results for 2024 were slightly below expectations, with total revenue of $627.7 million, falling short of the $630 million consensus. Although Ingrezza’s sales were in line with expectations at $615 million, they did not exceed them, which might have disappointed investors who anticipated a modest beat. Additionally, the company reported Non-GAAP EPS of $1.69, which was below the anticipated $1.99 due to higher expenditures in R&D and SG&A.
Another reason for the Hold rating stems from the company’s cautious sales guidance for Ingrezza in 2025, which is projected to be between $2.5 billion and $2.6 billion, below the midpoint consensus of $2.62 billion. This conservative outlook may suggest a potentially slower growth trajectory. Furthermore, Neurocrine’s increased R&D spending indicates a significant investment in developing their pipeline, which, while promising, also raises concerns about immediate profitability. These combined factors contribute to the decision to maintain a Hold rating on the stock.
NBIX’s price has also changed slightly for the past six months – from $145.630 to $150.510, which is a 3.35% increase.